Related Experiment Video

Updated: Aug 14, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Activation of p53 in MDM2-overexpressing cells through phosphorylation

C Gao1, T Nakajima, Y Taya

  • 1Department of Molecular Cellular Oncology, Tokyo Medical and Dental University, 1-5-45, Yushima, Tokyo, Bunkyo-ku, 113-8549, Japan.

Biochemical and Biophysical Research Communications
|November 2, 1999
PubMed

Insights

Anticancer drugs like etoposide activate wild-type p53 in MDM2-overexpressing Burkitt

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Overexpressed MDM2 protein is a common mechanism for inactivating wild-type p53 in human tumors.
  • The activation of wild-type p53 by anticancer drugs in the presence of excess MDM2 remains poorly understood.
  • Understanding p53 activation pathways is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the activation of wild-type p53 by anticancer drugs in MDM2-overexpressing cancer cells.
  • To elucidate the mechanisms underlying p53 activation and its consequences in Burkitt's lymphoma models.
  • To explore the therapeutic implications of p53 activation in MDM2-overexpressing tumors.

Main Methods:

  • Utilized Burkitt's lymphoma cell lines (BL2 with wt p53 and high MDM2, Raji with mutant p53).
  • Treated cells with topoisomerase II inhibitors (etoposide, doxorubicin) and specific inhibitors (wortmannin, Z-VAD, proteasome inhibitor).
  • Assessed p53 activation via phosphorylation, p21 and MDM2 levels, apoptosis, MDM2 degradation, and p53-MDM2 complex formation.

Main Results:

  • Etoposide and doxorubicin activated wild-type p53 (via Ser-15 phosphorylation) and induced apoptosis in BL2 cells (overexpressing MDM2).
  • p53 activation was accompanied by increased p21 and MDM2, partly inhibited by wortmannin; MDM2 degradation was not essential for p53 activation.
  • Activated p53 showed reduced complexation with MDM2, suggesting alleviated inhibition.

Conclusions:

  • Wild-type p53 can be activated by anticancer drugs through phosphorylation in MDM2-overexpressing cells, bypassing MDM2 inhibition.
  • Anticancer drug-induced p53 activation involves caspase-mediated downregulation of MDM2.
  • Targeting p53 activation in MDM2-overexpressing tumors represents a promising therapeutic strategy.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Concept Videos

DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...